Weil Company’s Bio-Rad Laboratories Class A BIO Stock Holding History

Weil Company’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-200	Closed	-$67K	–	138
2019 Q3	$67K	Buy	+200	New	+$65.2K	0.05%	165

Other funds holding BIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Weil Company's BIO Position: Q4 2019 in Review

Weil Company sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2019, closing a stake of 200 shares — an estimated $67K sold.

Weil Company first reported a position in BIO in Q3 2019 and held it in 1 quarter. The position peaked at $67K in Q3 2019. 386 funds tracked by Wall St. Rank hold BIO as of Q4 2019.

Weil Company reported no remaining Bio-Rad Laboratories Class A position as of Q4 2019 after selling out during the quarter.
Weil Company sold 200 Bio-Rad Laboratories Class A shares in Q4 2019, an estimated $67K.
Weil Company first reported a position in Bio-Rad Laboratories Class A in Q3 2019 and held it in 1 quarter.
Weil Company's Bio-Rad Laboratories Class A position peaked at $67K in Q3 2019.
386 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2019.

Based on Weil Company's 13F filing for Q4 2019, filed 13 Feb 2020.